Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-151364
Filing Date
2026-04-10
Accepted
2026-04-10 16:35:29
Documents
113
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K qncx-20251231.htm   iXBRL 10-K 3526659
2 EX-3.4 qncx-ex3_4.htm EX-3.4 13997
3 EX-23.1 qncx-ex23_1.htm EX-23.1 3989
4 EX-31.1 qncx-ex31_1.htm EX-31.1 15464
5 EX-31.2 qncx-ex31_2.htm EX-31.2 14749
6 EX-32.1 qncx-ex32_1.htm EX-32.1 12749
7 EX-32.2 qncx-ex32_2.htm EX-32.2 12368
8 GRAPHIC img158942542_0.jpg GRAPHIC 74075
  Complete submission text file 0001193125-26-151364.txt   16792188

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT qncx-20251231.xsd EX-101.SCH 2451817
117 EXTRACTED XBRL INSTANCE DOCUMENT qncx-20251231_htm.xml XML 3338306
Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

EIN.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-38890 | Film No.: 26855392
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)